vs
凯雷集团（CG）与奎斯特诊断（DGX）财务数据对比。点击上方公司名可切换其他公司
奎斯特诊断的季度营收约是凯雷集团的1.5倍（$2.9B vs $1.9B），凯雷集团净利率更高（18.8% vs 9.7%，领先9.1%），凯雷集团同比增速更快（84.1% vs 9.2%），过去两年凯雷集团的营收复合增速更高（66.2% vs 9.9%）
凯雷集团是美国知名跨国企业，核心业务涵盖私募股权投资、另类资产管理及金融服务领域。截至2023年，公司管理资产总规模达4260亿美元，是全球另类资管行业的重要参与者。
奎斯特诊断是美国头部临床检验服务商，位列《财富》500强，业务覆盖美国、波多黎各、墨西哥及巴西，同时与全球范围内多家医院、诊所保持长期协作关系，为不同地区的客户提供专业临床检验相关服务。
CG vs DGX — 直观对比
营收规模更大
DGX
是对方的1.5倍
$1.9B
营收增速更快
CG
高出75.0%
9.2%
净利率更高
CG
高出9.1%
9.7%
两年增速更快
CG
近两年复合增速
9.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.9B | $2.9B |
| 净利润 | $358.1M | $281.0M |
| 毛利率 | — | — |
| 营业利润率 | 24.3% | 15.4% |
| 净利率 | 18.8% | 9.7% |
| 营收同比 | 84.1% | 9.2% |
| 净利润同比 | 69.8% | 12.0% |
| 每股收益（稀释后） | $0.96 | $2.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CGDGX
| Q1 26 | — | $2.9B | ||
| Q4 25 | $1.9B | $2.8B | ||
| Q3 25 | $332.7M | $2.8B | ||
| Q2 25 | $1.6B | $2.8B | ||
| Q1 25 | $973.1M | $2.7B | ||
| Q4 24 | $1.0B | $2.6B | ||
| Q3 24 | $2.6B | $2.5B | ||
| Q2 24 | $1.1B | $2.4B |
净利润CGDGX
| Q1 26 | — | $281.0M | ||
| Q4 25 | $358.1M | $245.0M | ||
| Q3 25 | $900.0K | $245.0M | ||
| Q2 25 | $319.7M | $282.0M | ||
| Q1 25 | $130.0M | $220.0M | ||
| Q4 24 | $210.9M | $222.0M | ||
| Q3 24 | $595.7M | $226.0M | ||
| Q2 24 | $148.2M | $229.0M |
毛利率CGDGX
| Q1 26 | — | — | ||
| Q4 25 | — | 32.4% | ||
| Q3 25 | — | 33.7% | ||
| Q2 25 | — | 34.2% | ||
| Q1 25 | — | 32.5% | ||
| Q4 24 | — | 32.7% | ||
| Q3 24 | — | 32.6% | ||
| Q2 24 | — | 33.5% |
营业利润率CGDGX
| Q1 26 | — | 15.4% | ||
| Q4 25 | 24.3% | 13.8% | ||
| Q3 25 | 25.8% | 13.7% | ||
| Q2 25 | 28.0% | 15.9% | ||
| Q1 25 | 17.6% | 13.0% | ||
| Q4 24 | 25.7% | 13.8% | ||
| Q3 24 | 29.9% | 13.3% | ||
| Q2 24 | 20.5% | 14.8% |
净利率CGDGX
| Q1 26 | — | 9.7% | ||
| Q4 25 | 18.8% | 8.7% | ||
| Q3 25 | 0.3% | 8.7% | ||
| Q2 25 | 20.3% | 10.2% | ||
| Q1 25 | 13.4% | 8.3% | ||
| Q4 24 | 20.4% | 8.5% | ||
| Q3 24 | 22.6% | 9.1% | ||
| Q2 24 | 13.9% | 9.6% |
每股收益（稀释后）CGDGX
| Q1 26 | — | $2.24 | ||
| Q4 25 | $0.96 | $2.18 | ||
| Q3 25 | $0.00 | $2.16 | ||
| Q2 25 | $0.87 | $2.47 | ||
| Q1 25 | $0.35 | $1.94 | ||
| Q4 24 | $0.56 | $1.95 | ||
| Q3 24 | $1.63 | $1.99 | ||
| Q2 24 | $0.40 | $2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.0B | $393.0M |
| 总债务越低越好 | — | $5.7B |
| 股东权益账面价值 | $7.1B | $7.7B |
| 总资产 | $29.1B | $16.7B |
| 负债/权益比越低杠杆越低 | — | 0.74× |
8季度趋势，按日历期对齐
现金及短期投资CGDGX
| Q1 26 | — | $393.0M | ||
| Q4 25 | $2.0B | $420.0M | ||
| Q3 25 | $2.2B | $432.0M | ||
| Q2 25 | $1.3B | $319.0M | ||
| Q1 25 | $1.2B | $188.0M | ||
| Q4 24 | $1.3B | $549.0M | ||
| Q3 24 | $1.4B | $764.0M | ||
| Q2 24 | $914.8M | $271.0M |
总债务CGDGX
| Q1 26 | — | $5.7B | ||
| Q4 25 | — | $5.2B | ||
| Q3 25 | — | $5.2B | ||
| Q2 25 | — | $5.2B | ||
| Q1 25 | — | $5.9B | ||
| Q4 24 | — | $5.6B | ||
| Q3 24 | — | $5.6B | ||
| Q2 24 | — | $3.8B |
股东权益CGDGX
| Q1 26 | — | $7.7B | ||
| Q4 25 | $7.1B | $7.2B | ||
| Q3 25 | $6.8B | $7.3B | ||
| Q2 25 | $6.7B | $7.2B | ||
| Q1 25 | $6.4B | $6.9B | ||
| Q4 24 | $6.3B | $6.8B | ||
| Q3 24 | $6.3B | $6.8B | ||
| Q2 24 | $5.7B | $6.6B |
总资产CGDGX
| Q1 26 | — | $16.7B | ||
| Q4 25 | $29.1B | $16.2B | ||
| Q3 25 | $27.1B | $16.2B | ||
| Q2 25 | $25.1B | $16.0B | ||
| Q1 25 | $24.1B | $15.8B | ||
| Q4 24 | $23.1B | $16.2B | ||
| Q3 24 | $22.7B | $16.1B | ||
| Q2 24 | $22.3B | $13.9B |
负债/权益比CGDGX
| Q1 26 | — | 0.74× | ||
| Q4 25 | — | 0.72× | ||
| Q3 25 | — | 0.71× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | 0.85× | ||
| Q4 24 | — | 0.83× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | 0.58× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2B | $278.0M |
| 自由现金流经营现金流 - 资本支出 | $-1.2B | — |
| 自由现金流率自由现金流/营收 | -65.1% | — |
| 资本支出强度资本支出/营收 | 2.2% | 3.9% |
| 现金转化率经营现金流/净利润 | -3.34× | 0.99× |
| 过去12个月自由现金流最近4个季度 | $-3.4B | — |
8季度趋势，按日历期对齐
经营现金流CGDGX
| Q1 26 | — | $278.0M | ||
| Q4 25 | $-1.2B | $465.0M | ||
| Q3 25 | $-1.6B | $563.0M | ||
| Q2 25 | $-168.8M | $544.0M | ||
| Q1 25 | $-352.1M | $314.0M | ||
| Q4 24 | $-352.8M | $464.0M | ||
| Q3 24 | $791.9M | $356.0M | ||
| Q2 24 | $-1.3B | $360.0M |
自由现金流CGDGX
| Q1 26 | — | — | ||
| Q4 25 | $-1.2B | $307.0M | ||
| Q3 25 | $-1.6B | $419.0M | ||
| Q2 25 | $-186.3M | $436.0M | ||
| Q1 25 | $-368.8M | $197.0M | ||
| Q4 24 | $-379.5M | $341.0M | ||
| Q3 24 | $772.8M | $250.0M | ||
| Q2 24 | $-1.3B | $268.0M |
自由现金流率CGDGX
| Q1 26 | — | — | ||
| Q4 25 | -65.1% | 10.9% | ||
| Q3 25 | -475.7% | 14.9% | ||
| Q2 25 | -11.8% | 15.8% | ||
| Q1 25 | -37.9% | 7.4% | ||
| Q4 24 | -36.8% | 13.0% | ||
| Q3 24 | 29.3% | 10.0% | ||
| Q2 24 | -120.4% | 11.2% |
资本支出强度CGDGX
| Q1 26 | — | 3.9% | ||
| Q4 25 | 2.2% | 5.6% | ||
| Q3 25 | 7.0% | 5.1% | ||
| Q2 25 | 1.1% | 3.9% | ||
| Q1 25 | 1.7% | 4.4% | ||
| Q4 24 | 2.6% | 4.7% | ||
| Q3 24 | 0.7% | 4.3% | ||
| Q2 24 | 1.7% | 3.8% |
现金转化率CGDGX
| Q1 26 | — | 0.99× | ||
| Q4 25 | -3.34× | 1.90× | ||
| Q3 25 | -1732.78× | 2.30× | ||
| Q2 25 | -0.53× | 1.93× | ||
| Q1 25 | -2.71× | 1.43× | ||
| Q4 24 | -1.67× | 2.09× | ||
| Q3 24 | 1.33× | 1.58× | ||
| Q2 24 | -8.57× | 1.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CG
| Fund Management Fee | $606.8M | 32% |
| Other | $528.7M | 28% |
| Global Private Equity Segment | $307.3M | 16% |
| Global Credit Segment | $238.0M | 13% |
| Carlyle Alp Invest Segment | $124.6M | 7% |
| Incentive Fee | $55.4M | 3% |
| Fee Related Performance Revenues | $29.2M | 2% |
| Investment Advice | $11.1M | 1% |
DGX
暂无分部数据
